The pharmaceutical company Pfizer has applied for emergency approval for its Covid-19 drug Paxlovid in the United States.
The relevant documents have been submitted to the FDA, as Pfizer announced on Tuesday (local time).
The “overwhelming effectiveness” of the drug achieved in a recent study shows that antiviral therapies taken orally could play a decisive role in the fight against Covid-19, said CEO Albert Bourla.
According to the company from the beginning of November, the corona pill is very successful in preventing serious illnesses in high-risk patients.
An interim analysis of test results found Pfizer found the drug reduced the risk of hospitalization and death in Covid-19 patients by 89 percent, Pfizer said.
This applies to treatments within three days of the first Covid 19 symptoms; similar values would have resulted from treatments within five days.
The UK Medicines Agency (MHRA) recently approved the Lagevrio tablet (also known as molnupiravir).
The European Medicines Agency (EMA) announced at the end of October that it would examine the use of molnupiravir.